In the latest issue of Mayo Clinic Proceedings, Mayo Clinic researchers reviewed the importance of the microbiome as a key component of personalized medicine to improve diagnosis, reduce disease risk and optimize early detection and treatment. The microbiome is the combined genetic material of the microorganisms in a particular environment.

Surgery that doesn't involve the heart may cause damage to the heart in people with known or at high risk of developing heart disease and was  associated with an increased risk of death, according to new research in the American Heart Association's journal Circulation.

A new article in Mayo Clinic Proceedings reviews options for women going through genitourinary syndrome of menopause - an encompassing term for vaginal dryness, itching, dyspareunia and urinary tract infections brought on by low estrogen levels after menopause.

For J. William Charboneau, M.D., life is a journey of unknown possibilities, filled with family. And Tuesday, November 28, with family both personal and professional by his side and in the audience, Dr. Charboneau's journey reached another destination.

Fibroelastomas are formally known as papillary fibroelastomas, or PFEs, and are sometimes called cardiac papillomas. These small, noncancerous tumors develop in the heart - most often on one of the valves located between the heart chambers. Although they don't involve cancer, these tumors still pose a health threat, because they can increase your risk of developing blood clots that could lead to a heart attack or stroke. Treatment typically involves surgery to remove the tumor. If that's not possible due to other health considerations, then taking medication to lower the risk of blood clots is an option.

The U.S. Food and Drug Administration approved Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder (OUD) in adult patients who have initiated treatment with a transmucosal (absorbed through mucus membrane) buprenorphine-containing product. It is indicated for patients that have been on a stable dose of buprenorphine treatment for a minimum of seven days.